CO2-Patterns During Hyperoxia and Physical Exercise in COPD
CO2-Patterns During Hyperoxia and Physical Exercise in People With Severe COPD - a Randomized, Double-blind Cross Over Trial
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Rationale:
Carbon dioxide partial pressure (PCO2) varies significantly in patients with advanced chronic obstructive pulmonary disease (COPD). Data from the Swedish LTOT Registry showed that PCO2 is an independent predictor for mortality and that there is a U-shaped relationship. Patients with advanced COPD who are still normocapnic at rest may still develop a clinically relevant, exercise-induced carbon dioxide (CO2) retention during exercise/ activity. It is also known that altered breathing patterns at night in COPD patients can lead to nocturnal hypercapnia, especially during REM sleep. The course of PCO2 cannot be reliably predicted by lung function parameters or resting blood gas analysis. Since exercise tests with blood gas control or nightly PCO2 monitoring are rarely performed in clinical routine, exercise induced CO2 retention often remains undetected. In the literature, there is little information on PCO2 behaviour under everyday conditions (with or without LTOT) such as rest, physical exertion and nightly sleep. Therefore, predictors that could describe the PCO2 patterns are missing. However, one former study by O'Donnel from 2002 showed that the change in CO2 under hyperoxia conditions could provide predictive information for the change in CO2 with exercise.
Objective:
Primary aim of this study is to investigate whether the change of PCO2 during a hyperoxia-test (10l/min O2 at rest) correlates with the change of PCO2 during walking exercise with either a: l/min O2 as prescribed; b: medical air; c: 10l/min O2.
Design:
This study is a randomized, controlled cross-over trial. Following an initial maximal incremental shuttle walk test (ISWT), the participant will perform 3 endurance shuttle walk tests (ESWT) at 85% of the maximum ISWT pace on three consecutive days (24h break between ESWTs). In a randomized order, participants will perform one ESWTs with O2-flow as prescribed (e.g. study day 1), one with medical air (same flow rate as prescribed oxygen) (e.g. study day 2) and one with 10l/min O2 (e.g. study day 3). An additional hyperoxia test (10l/min O2 for ten minutes; at resting condition) will be perfomed on each day prior to performing an ESWT.
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Tessa Schneeberger
- Número de teléfono: +498652931540 +498652931540
- Correo electrónico: TSchneeberger@Schoen-Klinik.de
Ubicaciones de estudio
-
-
-
Schönau am Königssee, Alemania, 83471
- Reclutamiento
- Klinikum Berchtesgadener Land, Schön Kliniken
-
Contacto:
- Tessa Schneeberger, MSc
- Número de teléfono: 0049 - 8652 - 932730
- Correo electrónico: tschneeberger@schoen-klinik.de
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- COPD III/ IV
- 35mmHg < PCO2 <= 55mmHg (under resting conditions, breathing room air)
- Hypoxemia (PaO2<60mmHg) under room air conditions (rest or during exercise) or SpO2 <88% during exercise
- established oxygen therapy or given indication for oxygen therapy
- written informed consent
Exclusion Criteria:
- acute exacerbation of COPD
- exercise limiting cardiac or orthopedic comorbidites
- PaO2 <50mmHg at rest, breathing room air
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Randomised to begin with oxygen-supplementation at 10L/min during ESWT
Randomised order of tests starting with the 10L/min O2, during the ESWT followed by prescribed O2 flow rate or medical air in randomised order on seperate days
|
Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
|
|
Experimental: Randomised to begin with medical air supplementation at prescibed O2 flow rate during ESWT
Randomised order of tests starting with the medical air during the ESWT followed by prescribed O2 flow rate or 10L/min O2 in randomised order on seperate days
|
Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
|
|
Experimental: Randomised to begin with oxygen supplementation at prescibed O2 flow rate during ESWT
Randomised order of tests starting with the prescribed O2 flow rate, during the ESWT followed by 10L/min O2 or medical air in randomised order on seperate days
|
Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in PCO2 during hyperoxia at rest
Periodo de tiempo: Change from baseline to after 10 minutes breathing 10L/min oxygen
|
pCO2 measured by capillary blood gases taken before and after the hyperoxia test
|
Change from baseline to after 10 minutes breathing 10L/min oxygen
|
|
Change in PCO2 from rest to end exercise (endurance shuttle walk test)
Periodo de tiempo: Change from baseline to the end of the ESWT, up to 20 minutes
|
pCO2 measured by capillary blood gases taken before and after the ESWT
|
Change from baseline to the end of the ESWT, up to 20 minutes
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Transcutaneous partial pressure of CO2 (TcPCO2) during hyperoxia test
Periodo de tiempo: Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
TcPCO2 measured by continuous transcutaneous recording via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)
|
Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
|
Transcutaneous partial pressure of CO2 (TcPCO2) during endurance shuttle walk test
Periodo de tiempo: Continuously during ESWT, up to 20 minutes
|
TcPCO2 measured by continuous transcutaneous recording via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)
|
Continuously during ESWT, up to 20 minutes
|
|
Breathing frequency during hyperoxia test
Periodo de tiempo: Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
Breathing frequency during the hyperoxia test measured by ApneaLink Air™ (ResMed)
|
Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
|
Breathing frequency during endurance shuttle walk test
Periodo de tiempo: Continuously during ESWT, up to 20 minutes
|
Breathing frequency during the ESWT measured by ApneaLink Air™ (ResMed)
|
Continuously during ESWT, up to 20 minutes
|
|
Heart rate during endurance shuttle walk test
Periodo de tiempo: Continuously during ESWT, up to 20 minutes
|
Heart rate measured by continuous transcutaneous recordung via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)
|
Continuously during ESWT, up to 20 minutes
|
|
Heart rate during hyperoxia test
Periodo de tiempo: Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
Heart rate measured by continuous transcutaneous recordung via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)
|
Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
|
Change of capillary partial pressure of O2 (pO2) during endurance shuttle walk test
Periodo de tiempo: Change from baseline to the end of the ESWT, up to 20 minutes
|
pO2 measured by capillary blood gases taken before and after the ESWT
|
Change from baseline to the end of the ESWT, up to 20 minutes
|
|
Change of inspiratory capacity during endurance shuttle walk test
Periodo de tiempo: Change from baseline to the end of the ESWT, up to 20 minutes
|
IC measured by SpiroSense (Pari) before and after the ESWT
|
Change from baseline to the end of the ESWT, up to 20 minutes
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CO2-Hyperoxia & Exercise
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .